

Colorectal cancer in symptomatic patients: how to improve the diagnostic pathway.

William Hamilton and Sarah Bailey

William Hamilton, Professor of Primary Care Diagnostics, University of Exeter, UK (corresponding author)

Sarah Bailey, Associate Professor of Primary Care, University of Exeter, UK

College House,

St. Luke's Campus,

Magdalen Road,

Exeter EX1 1SR,

UK

Abstract

Even in countries with national screening programmes for colorectal cancer, most cancers are identified after the patient has developed symptoms. The patients present these symptoms usually to primary care, or in some countries to specialist care. In either healthcare setting, the clinician has to consider cancer to be a possibility, then to perform triage investigations, followed by definitive

investigation, usually by colonoscopy. This apparently simple pathway is not simple: most symptoms of colorectal cancer are more likely to represent benign disease than cancer, and each of these stages represents selection of patients into a higher-risk pool. This article summarises a symptom-based approach to selection and initial investigation of such patients in primary care. Some special groups need particular attention, including the younger patient, those with an inherited predisposition to cancer, and those with co-morbidities.

Key words: primary health care, diagnosis, colorectal cancer, symptoms

1 Introduction

The main pathway to diagnosis for colorectal cancer is following a symptomatic presentation, either in primary care, or direct to specialist. Thus, improving the symptomatic pathway is key to improving patient outcomes and survival. Achieving improvement in the pathway requires a multifaceted approach, including increasing awareness of the disease in the public, optimising triage strategies in primary care, and improving access to diagnostic tests.

1 The benefits of expedited symptomatic colorectal cancer diagnosis

It is largely accepted that expedited diagnosis of symptomatic cancer yields benefits. These are generally considered from the aspect of improved survival, though morbidity benefits may also accrue. These mortality benefits include reduced psychological distress, often less onerous treatment (with fewer side-effects) and sometimes less extensive surgery. There are also cost-benefits, arising from reduced treatment, though this ignores any extra costs of the enhanced diagnostic services needed to expedite the diagnosis (1).

A systematic review published in 2015 concluded that shorter time to diagnosis in colorectal cancer is generally associated with better patient outcomes (2). However, most of the papers in that systematic review were observational studies, largely because randomized trials in the diagnostic arena require very large numbers, and are expensive. They also raise ethical problems, as by their very nature those not receiving an intervention may receive a slowed diagnosis. Many of the studies in the systematic review showed a U-shaped curve, with worse survival for both short times to diagnosis and for long times to diagnosis, and the best survival for times to diagnosis near the median time to diagnosis – which was usually

around a month. This phenomenon of worse survival in those diagnosed rapidly, the 'waiting time paradox', was explored further in a large analysis of six international datasets of colorectal cancer diagnosis. The poorer survival with short diagnostic intervals was considered to represent the very ill patients, already destined to have a poor prognosis, but in whom diagnosis was relatively easy (the so-called 'sick-quick'). Many of these patients will have suffered an emergency complication of their cancer, which brings extra mortality as well as being associated with worse cancer staging (3)

If the 'sick-quick' patients are removed from consideration, then survival worsens with diagnostic delay almost linearly. In a sophisticated modelling exercise Sud et al estimated survival disadvantage caused by the COVID-19 pandemic for most cancers (4). Survival for colorectal cancer was worsened by a 2-month delay in a range of 6.4 -10.7%, with the smaller reductions being in younger ages. In broad terms this equates to a survival disadvantage of around 1% per week of delay. These figures have to be compared with the benefits accruing from adjuvant treatment. It may be that all the survival benefits from adjuvant treatment are of the same magnitude as the survival losses from one month of delay in diagnosis after symptoms have begun.

More evidence for survival gains from expedited diagnosis comes from screening studies [ref Screening paper in this series]. The introduction of bowel screening in the UK was associated with significant reductions in emergency admissions (5). However, currently the UK national screening programme – which is well organised, and free for users – identifies fewer than 10% of all UK colorectal cancers (6). Symptomatic detection remains the main route to diagnosis in the UK.

One final point on the survival benefits which arise from expedited symptomatic diagnosis. Some colorectal cancers that are identified in patients investigated for bowel symptoms were not the cause of the symptoms and were found by chance. Not surprisingly these cases are more likely to be found at an early disease stage and have a better prognosis. The percentage of serendipitously found colorectal cancers has been estimated to be between 12 and 32% (7). There is a positive relationship between the use of suspected cancer investigations in primary care at a practice level, and cancer survival. This advantage has been shown for all cancers collectively (8) and for oesophagogastric cancer specifically (9) though has yet to be examined for colorectal cancer specifically.

In summary, there is mounting evidence for survival benefits from expedited diagnosis of symptomatic colorectal cancer. Indeed, this may be the cancer site with the strongest evidence for the benefits of earlier detection.

2 The challenge for primary care

Given that screening picks up such a small minority of cases even in countries with comprehensive screening programmes, most strategies aimed at improving the diagnostic pathway for CRC target the symptomatic patient population. These strategies have two components: identifying who should be investigated for possible colorectal cancer, and how should they be tested. We concentrate on the first of these – selection of patients for testing – as faecal immunochemical testing (FIT) has greatly simplified testing in UK primary care (10). Before FIT was available, and in countries where it is yet to be introduced, patients who had been identified as having possible colorectal cancer could only be offered colonoscopy, CT, or CT colonography, with a small number being offered capsule endoscopy, though the last of these has yet to be rigorously evaluated in the symptomatic population. Each of these

tests is moderately expensive and requires colon preparation. Complications can occur, plus CT delivers a radiation load. Therefore, in most developed countries definitive investigation by one of these testing modalities has been targeted at those most likely to have cancer – that is the higher-risk population. This principle of preferentially investigating the highest-risk patients used in the National Institute for Health and Clinical Excellence Guidelines in the UK, initially in their 2005 document, Referral Guidelines for Suspected Cancer. An explicit threshold of a risk of cancer of 3% or higher warranting urgent investigation was the basis for revised guidance from NICE, published in 2015 (11)

NICE guidance pertains to England and Wales, and is generally followed in Northern Ireland. Scotland has its own guidance, which does not explicitly report a threshold cancer risk for referral. Since publication of NG12 in 2015, the focus within cancer diagnostic research has moved away somewhat from cancer-site centered studies to studies of non-specific features. This term is used to mean features that may represent cancer, but without a specific tie to one particular site or type. Thus, there are recent studies of weight loss (12), abdominal pain (13), thrombocytosis (14) and microcytosis (15) – all with some relevance to colorectal cancer.

3 Features of colorectal cancer

The alarm features of colorectal cancer include rectal bleeding, anemia, change in bowel habit, and weight loss; evidence for the clinical value of these features was explored in a recent systematic review (16). There is an association between some symptoms of colorectal cancer and the cancer stage at diagnosis (17), with rectal bleeding, change in bowel habit, abdominal pain and weight loss increasingly more likely to represent more advanced stage. However, any of the features of colorectal cancer can be found at any stage. In particular,

there is no symptom (or pattern of symptoms) which is characteristic of early-stage disease. Therefore, we present symptoms throughout this paper in approximate order of risk. These are summarized in Table 1.

Feature of colorectal cancer	Approximate risk of colorectal cancer (PPV)	Approximate frequency in primary care series (18)	Notes
Anaemia	In meta-analysis 5.9%	27%	PPVs higher with iron deficiency and with severity (19)
Rectal/abdominal masses	unknown	Unknown, but likely to be very low	
Rectal bleeding	In meta-analysis 4.8%	42%	PPVs higher with recurrent bleeding (20)
Weight loss	<1% in meta-analysis of a systematic review (21)	27%	The PPV increases with increasing weight loss (22)
Abdominal pain	In meta-analysis, 1.0% (11)	42%	0.32% in a large recent study (13)
Diarrhoea	0.9% (18)	38%	
Constipation	0. (18)	26%	

Change in bowel habit	3.9-14% (22,23)	20% (23)	See discussion of these three terms in text
Thrombocytosis	2.3% in males; 1.2% in females (14)	unreported	

Table 1. The major symptoms of colorectal cancer in primary care

3.1 Anaemia

Anaemia arises in colorectal cancer because of bleeding into the colon. This may be invisible, or not be noticed by the patient. This gastrointestinal bleeding is the rationale for faecal immunochemical testing and its predecessor, guaiac testing. The bleeding may also explain the increased platelet count (thrombocytosis) described in more detail below. Prolonged bleeding may deplete iron stores, which are easily measurable – most usually as a ferritin estimation. The red cell volume may also fall, causing microcytosis. Indeed, microcytosis without anemia still represents a small risk of colorectal cancer (15). As would be expected the risk of colorectal cancer increases as the value of haemoglobin falls, and with increasing patient age (19).

Anaemia may present with symptoms of fatigue or dyspnea, but most commonly is identified as part of a full blood count having been undertaken without colorectal cancer necessarily being suspected. Even so, the mere decision to perform a full blood count selects a population at higher risk of cancer (an approximate doubling of risk). Counter-intuitively, even if the haemoglobin is normal, such patients remain at a higher risk than the population norm (24). This is simply because the reassurance derived from the normal haemoglobin is smaller than the selection effect in the initial decision to test.

A similar counter-intuitive effect is seen with worse survival outcomes in those with mild anaemia as their first symptom when compared to more severe anaemia (25). Indeed, those with mild anaemia are more likely to present with an emergency complication of their cancer than their severe anaemia counterparts (26). This is probably a further manifestation of the 'sick-quick' waiting time paradox, whereby patients with severe anaemia are referred for investigation without delay, yet those with milder anaemia are investigated more slowly (or not at all).

The assumption that anaemia from colorectal cancer develops slowly and has accompanying features such as microcytosis underpinned a study from Israel, where routine annual full blood counts are offered to the adult population (27). This routine testing eliminates the selection bias referred to above. However, the performance characteristics of the algorithm were insufficient to support clinical adoption. Several groups are currently examining whether study of primary care blood results with artificial intelligence techniques can produce a useful algorithm.

Investigation of anaemia must consider other possibilities, including benign colonic conditions, upper gastrointestinal lesions – both benign or malignant – nutritional deficiency and drug side-effects, plus several other conditions. Indeed, many other cancers may cause anaemia, so there is interest in investigation for cell-free DNA, in the so called multi-cancer detection test. Secondary care studies have reported good diagnostic performance for such tests, which not only identify methylated DNA as a marker of probable cancer, but can suggest possible cancer sites. Major studies of these multi-cancer detection tests are underway, including in the symptomatic population. As yet, the evidence base is insufficient to support their use in patients with possible colorectal cancer, though this may change.

3.2 Rectal/abdominal masses.

These are rare but high-risk presentation of colorectal cancer. There is no high-quality evidence from primary care on these features, reflecting their rarity, and perhaps the obvious clinical action to be taken if such a mass is encountered. Nonetheless, it is clear that not all masses that are identified are malignant – though they still warrant investigation.

3.3 Rectal bleeding

Rectal bleeding is the commonest presentation of colorectal cancer. For this reason, many different pathways have been used to facilitate rapid investigation of this feature. To an extent this strategy has worked – in England it is the symptom with the shortest time to diagnosis, which may explain the better survival for colorectal cancer patients who present with this symptom when compared to other features of the disease (25,28). These pathways may now be redundant in the FIT era. It appears counter-intuitive to request a FIT in a patient who describes rectal bleeding: however, the performance characteristics of FIT in primary care are similar whether the population includes or excludes patients with this symptom. The use of FIT in this population also sidesteps the problem of whether to investigate the whole bowel (but colonoscopy or CT colonography) or whether to examine the left side of the bowel (by sigmoidoscopy) as rectal bleeding can occasionally arise from the right side of the bowel.

Studies have examined specific characteristics of rectal bleeding or accompanying symptoms (18,29). These reported that the presence of perianal symptoms – such as itching – identified a lower risk population with rectal bleeding. The assumption was that haemorrhoids or anal fissures were a more likely explanation and that investigation for possible colorectal cancer could be delayed or even averted. Later studies did not support

this view, and given the relative simplicity and inexpensiveness of FIT, it is now deemed appropriate to perform this test irrespective of accompanying features.

3.4 Weight loss

This symptom in isolation carries a lower risk for colorectal cancer than those discussed earlier in this section. However, the incidence of any cancer type following unexplained weight loss in primary care is 2.2%, from a recent large study of electronic primary care records (12). It is likely that there are other symptoms accompanying the loss of weight when it is caused by colorectal cancer, but it is still logical to request a FIT in most patients with unexpected weight loss. Like anaemia, this symptom is a candidate for multi-cancer detection tests, so investigation may switch from FIT and imaging to such tests if they are shown to be useful in current studies. The amount of weight loss required to trigger investigation is unknown, though a loss of greater than 10% of the patient's 'normal' weight has a PPV of roughly twice that for weight loss of 5-10%, across all ages and both sexes (22). It is often difficult to assess the 'normal' weight, particularly as recording of weight in primary care is infrequent.

3.5 Abdominal pain

Several studies have reported an association between abdominal pain and a future diagnosis of colorectal cancer, albeit with low positive predictive values (PPVs) for all cancer types studied. The systematic review undertaken as part of the development of NICE Guidance NG12 (11) identified eight studies, five of which entered meta-analysis. The summary PPV was 2.04% (95% confidence intervals 0.53-7.55) though one study was a clear outlier. Following removal of this study, the summary PPV was 1.02 (0.36-2.69). One large study published after the NICE review reported an even lower PPV of 0.32% (13). This reflects the large number of benign conditions, and non-colorectal cancers, which can cause abdominal

pain. However, that brings the risk of misdiagnosis, including of irritable bowel syndrome. Unfortunately, most of the studies were based on retrospective examination of medical records, so further characterization of the abdominal pain was inconsistent or missing.

Despite its relatively low PPV, abdominal pain cannot be ignored as a symptom of possible cancer. Like mild anaemia, it is particularly associated with poorer outcomes (and with emergency presentations) (25). Indeed, this may be because of its low PPV, encouraging clinicians to consider other possible diagnoses instead of cancer. This was particularly relevant in the pre-FIT era, where investigation to rule out cancer necessitated colonoscopy or sigmoidoscopy, preceded by administration of bowel preparation. Fortunately, the performance of FIT has eased the problem of whether (and how) to investigate low-risk colorectal cancer symptoms in primary care.

3.6 Constipation, diarrhea and change in bowel habit.

Clearly these terms overlap, but change in bowel habit is more than just an umbrella term covering both constipation and diarrhoea. It is a term used only by the medical profession (in forty years of clinical practice, WH never had a patient who used that expression). It means more than just constipation or diarrhoea or both. It has an unspoken extra meaning: 'constipation or diarrhea, and I think colorectal cancer is possible'. This last clause is crucial, even if unspoken. Medicolegally, if a UK general practitioner documented change in bowel habit in the patient's records and chose not to investigate, they would be deemed negligent. This would not necessarily be the case for records of constipation or diarrhoea. This terminological difference is reflected in very different PPVs, as seen in Table 1. PPVs for change in bowel habit are generally four or times higher than for diarrhoea or constipation. In effect this difference reflects the doctor's holistic assessment – which may be of other symptoms, or may be a subtle intuition that the constipation or diarrhoea is of greater

concern. General practitioners' ability to select sub-populations at higher (and lower) risk has been studied in a report of high-risk symptoms of cancer (30). In over 13,000 patients having rectal bleeding in their records, only 17.7% received a referral for possible colorectal cancer, despite national guidance recommending it. However, the percentage of patients who were referred who transpired to have cancer was 6.4%, and only 1.5% in those un-referred (but who later must have been investigated). In short, general practitioners have the skills to identify higher risk patients – and with disorders of bowel transit, to label them change in bowel habit.

3.7 Thrombocytosis

Thrombocytosis is a platelet count above a normal range, though this normal range varies between laboratories and the sexes. Two large studies have examined the association between thrombocytosis and colorectal cancer. Both were large and retrospective, and utilized existing medical and laboratory records plus cancer registries. The first from the UK, used a threshold range of 400×10^9 /litre to define abnormality, and identified a PPV for colorectal cancer of 2.3% in males and 1.2% in females (likely due to the fact that average female platelet counts are higher, with mildly abnormal counts more frequent, thus 'diluting' the cases) (14). Similar results were reported from a Canadian study, which found a PPV of 1.2% using a threshold of 450×10^9 /litre to define abnormality (31). These figures are high enough to suggest a FIT should be offered when thrombocytosis is identified. It is also possible that the platelet count can be used in anaemic patients to help identify a higher risk sub-population warranting urgent investigation. This is currently being studied.

4 Tools to assist the general practitioner

It is clear from the above that colorectal cancer can present in several ways: indeed the described features of colorectal cancer are often found together (and represent higher PPVs when they do). However, many of the symptoms are extremely common in the non-cancer population. Therefore, it is not surprising that doctors may simply not consider the possibility of cancer in many of these presentations, resulting in increased time to diagnosis. A second broad reason for diagnostic delay occurs when cancer is considered, but there are barriers to investigation.

The first of these problems can be addressed by providing cancer diagnostic information to general practitioners in a way that reduces the chance that cancer will not be considered. This information can be delivered in several ways. To illustrate these, we reference Risk Assessment Tools, a group of 18 adult charts (one for each common adult cancer) showing the risk of cancer for symptoms expressed as a PPV. Other tools exist, including QCancer, which covers fewer cancer sites, and is only available in electronic form. Initially, Risk Assessment Tools (or RATs) were given to all English general practitioners in mousemat and calendar forms, and covered only colorectal and lung cancer (see Figure 1).




Figure 1. A lung and colorectal Risk assessment tool in mouse mat form.

Each cell in the top row reports the risk of colorectal cancer for a single symptom, colour-coded to reflect the risk. Cells on the intersect of two symptoms reported the risk when both symptoms were present (strictly, when they had been reported within the same 24 month period, though they were usually very close together). Finally cells on the diagonal reported the risk when a symptom had been reported at least twice (again within a 24 month period).

The next phase in development was to integrate RATs into general practitioners' computers, so that they would automatically search the patient's medical record for reports of any of the symptoms, and then calculate the risk of cancer represented by this symptom or symptoms. These were named eRATs to differentiate them from the paper/mouse mat forms earlier. If the risk was above an agreed level a prompt would show on the GP's computer screen (see Figure 2). We chose a 2% risk as a balance between aspiring to diagnose cancer earlier vs. avoiding generating so many prompts that the GP may end up ignoring many. This so-called 'prompt fatigue' is a genuine phenomenon.




Figure 2. A sample prompt from an eRAT, based on a fictitious patient.

The early work in eRATs was supported by a UK Cancer charity, Macmillan, who distributed them to interested general practitioners. By 2015, cancer decision support tools were available in just over a third of English practices, though only half of such practices actually reporting using them (32).

A large cluster-randomized trial is currently under way to examine the clinical and cost-effectiveness of eRATs (the ERICA trial) (33). In over 400 practices, eRATs for six adult cancers (including colorectal) have been installed in the intervention practices. The primary outcome of the trial is stage at diagnosis, as this is so clearly linked with survival. Multiple secondary outcomes are being examined, as well as a process evaluation and economic

arms. Practice recruitment ceased in April 2022, and the trial runs for 24 months. The cancer outcome data is to be extracted from routine cancer registry records, so that the final result should be available in late 2025.

5 Education and guidance

The clinical decision support in the form of RATs and QCancer are also educational.

However, the most influential form of education/guidance in the UK has been NICE guidance, most notably NG12, Suspected Cancer: recognition and referral (11). This was published in 2015, and replaced guidance for 2005. The colorectal guidance was controversial in recommending testing for blood in faeces, a test strategy that had been abandoned many years before, because of the level of false-negatives. Awkwardly, at the time of NICE's systematic reviews there was very little primary care evidence on the use of FIT in the symptomatic population, whereas there was supportive evidence for the older guaiac test, or faecal occult blood test (FOB). Thus the 2015 recommendation for testing for 'occult blood in faeces' had to be later replaced by a recommendation for FIT in a second NICE guidance, DG30 (34).

Despite the controversy, this colorectal guidance has resulted in reduced times to diagnosis. A study examined the time to diagnosis for colorectal cancer symptoms newly introduced in 2015 ('new symptoms'), and compared them to times to diagnosis for symptoms that were present in both the previous 2005 guidance and the 2015 guidance ('old symptoms') (35). Before the 2015 guidance was issued, not surprisingly, patients with old symptoms had their colorectal cancer diagnosed more rapidly than patients with new symptoms (which were of course not in the guidance at all). After 2015, patients with new symptoms had more rapid diagnoses, initially matching those of patients with old symptoms, and eventually doing

better, so that at the end of the study patients with new symptoms were receiving a faster diagnosis than those with 'old' traditional symptoms.

However, education and guidance is only as good as the research upon which it is based.

Some problem areas in colorectal diagnostic research remain. In particular, characteristics of symptoms such as duration and severity have very little research support. Proxies such as re-attendance with the symptom are of some value, but it is simply unknown what the risk of colorectal cancer is for say 2 weeks of diarrhoea as opposed to six weeks of diarrhoea.

Clinical experience suggests the longer duration is likely to represent a higher risk, but is the risk increase linear? And for how long does the risk rise? It seems to rise with each primary care presentation with abdominal pain (at least up to the sixth presentation(18)) but beyond that is unknown, and it is likely other diseases such as irritable bowel syndrome, become much more likely if the symptom has persisted over a year. Research in this area is difficult, but there is an unmet need for it.

6 Younger patients

Colorectal cancer in the under 50-year-old age group is increasingly common; the incidence in this age group has almost doubled in the last 30 years (36). Some reasons for this are given in an earlier paper in this issue [ref], with lifestyle factors being more relevant than inheritable predisposition, in that around a fifth only of cancers in this age group are found to have a recognized genetic predisposition (37). The symptoms in younger patients are no different to those in older patients (Figure 3) (38).

Rectal bleeding	Rectal mass	Change in bowel habit	Constipation	Diarrhoea	Abdominal pain	Nausea and/or vomiting	Low haemoglobin	Raised inflammatory markers	Low mean red cell volume	
0.4 [0.3 to 0.6]	0.6 [0.3 to 1.1]	0.5 [0.2 to 1.0]	0.1 [0.1 to 0.2]	0.1 [0.1 to 0.1]	0.1 [0.1 to 0.1]	0.1 [0.1 to 0.1]	0.1 [0.1 to 0.1]	0.1 [0.1 to 0.1]	0.1 [0.1 to 0.2]	PPV as a single symptom
1.8 [-]	17 [-]	0.3 [-]	5.8 [-]	0.4 [-]	0.4 [-]	1.3 [-]	13 [-]	1.4 [-]	8.6 [-]	Rectal bleeding
	5.4 [-]	6.3 [-]	4.1 [-]	5.1 [-]	7.0 [-]	1.3 [-]	5.8 [-]	7.0 [-]	2.9 [-]	Rectal mass
		1.2 [-]	0.3 [-]	4.1 [-]	0.3 [-]	0.3 [-]	5.1 [-]	0.4 [-]	2.1 [-]	Change in bowel habit
			0.3 [0.1 to 0.7]	1.8 [-]	0.3 [0.1 to 0.6]	0.5 [-]	0.4 [-]	1.0 [-]	5.1 [-]	Constipation
				0.1 [0.1 to 0.2]	0.2 [0.1 to 0.3]	0.1 [-]	0.4 [-]	0.3 [0.1 to 0.6]	0.7 [-]	Diarrhoea
					0.2 [0.1 to 0.3]	0.1 [0.1 to 0.3]	0.5 [0.3 to 1.2]	0.3 [0.2 to 0.6]	0.7 [-]	Abdominal pain
						0.1 [0.1 to 0.2]	0.3 [-]	0.2 [-]	0.2 [-]	Nausea and/or vomiting
								0.4 [0.2 to 0.6]	0.2 [0.2 to 0.4]	Low haemoglobin
									0.4 [0.2 to 0.7]	Raised inflammatory markers

Figure 3. PPVs (95% CI) for colorectal cancer (CRC) in males and females aged 18–49 years for individual risk markers and for pairs of risk markers in combination. PPV = positive predictive value. (reproduced with permission from Stapley et al).

However, because of the relative rarity of colorectal cancer, each specific symptom (or pair of symptoms) has a lower PPV – often much lower -than in studies including all ages. This creates a problem for primary care in that a general practitioner is less likely to consider cancer than they would have been for the same symptom in an older patient. Furthermore, most inflammatory bowel disease is first experienced below the age of 50. These diseases share some symptoms, so that in this age group it is more likely that a patient reporting one or more of these symptoms has inflammatory bowel disease than cancer. The main primary care test for inflammatory bowel disease, calprotectin, does not reliably also identify cancer, so if such patients are investigated with calprotectin alone, cancer may not be identified. FIT may help, but again both diseases exhibit rectal bleeding (39). All these factors mean that

diagnosis may be delayed: indeed the stage distribution and thus long-term survival have been reported to be worse in younger patients than older patients (40).

There is no simple solution to diagnosis of colorectal cancer in younger patients. Increased use of FIT, and of calprotectin, should identify patients in whom definitive bowel investigation by colonoscopy is warranted. However, that requires the clinician to have thought of cancer (or inflammatory bowel disease) in the first place. It is plausible electronic prompts could help here, though this is as yet unknown.

7 Factors affecting risk

7.1 Genetic risk

Lynch Syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is an inherited genetic disorder that predisposes affected individuals to several cancer types, including colorectal, endometrial, ovarian, gastric, and pancreatic. Lynch syndrome is associated with a much higher lifetime risk of developing colorectal cancer than the general population; estimated to be between 52-82% (41), compared to 5-6% in the general population. The risk of early onset (before age 50 years) colorectal cancer is much higher in Lynch Syndrome (42).

There is no routine testing for Lynch Syndrome in the UK; rather, targeted screening is recommended for individuals with a personal or family history of colorectal or other Lynch syndrome-associated cancers (7). Thus, identification of patients occurs after the suspicion, or confirmation, of cancer has been raised, making this knowledge of limited use in the investigation of symptomatic patients in primary care. Regular screening for colorectal cancer in individuals identified with Lynch includes colonoscopies every one to two years from 25 years of age (43). Five-year survival from colorectal cancer diagnosis in patients with

Lynch was found to be 90% in a meta-analysis (44); it is only around 50% in all cases in the UK(45), perhaps reflecting the impact of regular colonoscopy screening in the former group.

Genetic risk scores (GRS) have recently attracted interest as a potential tool to identify individuals at risk of cancer, who could then be monitored, or investigated in primary care when they present with nonspecific signs of disease (46). Research on the impact of GRS in the symptomatic pathway is limited to prostate cancer so far (47), but research into the potential use of a colorectal cancer GRS is ongoing.

7.2 Chronic health conditions

Several chronic health conditions are known to have an effect on colorectal cancer risk; however, little is known about the impact these conditions may have on symptomatic presentation. Diabetics have an increased risk of developing colorectal cancer compared to non-diabetic patients (relative risk 1.28; 95% CI 1.19-1.39) (48); this increase may be due to several factors, including insulin resistance, chronic inflammation, and hyperglycemia, which are all characteristics of diabetes and have been linked to cancer development (49). Hypertension (50), obesity (51), inflammatory bowel disease (52) are also known to increase colorectal cancer risk, although the mechanisms underpinning these links is not fully understood. Despite this, current guidance for primary care in investigating symptomatic patients does not offer alternative options depending on the presence (or absence) of comorbidities (11).

8 Testing strategies

Access to diagnostic tests is an important factor in improving the diagnostic pathway for colorectal cancer. The issues surrounding access to tests varies depending on the healthcare

system; in the UK, some tests are available for general practitioners in primary care, with others requiring referral to secondary care. Waiting times for investigations such as colonoscopies can be lengthy in the UK (although this is less of a concern in other countries), a problem compounded by the COVID-19 pandemic, from which the service is still recovering. This can delay diagnosis and treatment, which can impact patient outcomes.

One approach to improving access to diagnostic tests in primary care is to increase the use of non-invasive diagnostic tests. Faecal immunochemical tests (FIT) test for the presence of haemoglobin in a faecal sample. They can be ordered directly in primary care and completed by the patient at home, which can help to reduce the burden on healthcare systems and improve access for patients. FIT is in widespread use in the UK, with variable use in other countries.

Faecal DNA tests are an emerging point-of-care test which detect specific genetic alterations and epigenetic changes associated with colorectal cancer in faecal samples. The detection of these biomarkers can indicate the presence of colorectal cancer or its precursor lesions.

Faecal DNA tests have not been evaluated extensively in the primary care setting; a systematic review published in 2020 concluded that these tests may be useful for colorectal cancer detection, but that candidate tests need to be evaluated in large longitudinal studies in both symptomatic and asymptomatic populations (53). Long-term studies assessing the impact of faecal DNA testing on colorectal cancer incidence and mortality are underway to establish its role in population-based screening programs and in symptomatic detection.

Capsule colon endoscopy (CCE) uses advanced imaging technology to create a detailed image of the colon, which can help to identify abnormalities and lesions. It offers an alternative to the traditional colonoscopy and has the advantage of being less invasive than that traditional method, eliminating the need for sedation. The patient swallows the capsule, containing a camera and a light, which captures footage of the bowel as it moves through the patient. The footage is collected by an external recording device. CCE is

currently available in secondary care and is a potential addition to the primary care pathway. CCE has been demonstrated to be more tolerable to patients than the traditional colonoscopy (54). This can lead to improved compliance and increased participation rates in testing. The method enables the entire colon to be imaged, including regions which may be challenging to reach with a traditional colonoscopy. However, finding and training staff in interpreting the outputs remains a challenge, and the diagnostic accuracy in the primary care population is unknown. CCE cannot biopsy any suspicious region or perform therapeutic tissue removal, so a follow up with a traditional colonoscopy is still required in patients who test positive, either for biopsy or for polyp removal. There are also issues with incomplete imaging of the bowel, image quality, and in some cases capsule retention. Factors such as bowel motility, bowel preparation quality, and anatomical variations can impact the procedure's effectiveness.

In addition to these approaches, there is also a need to improve the coordination and communication between healthcare providers in the diagnostic pathway. This can help to ensure that patients receive timely and appropriate care, and that the diagnostic process is as efficient as possible.

9 Patient awareness

Improving symptomatic colorectal cancer detection in primary care settings relies on patients finding their way to primary care with their symptoms. A number of public health campaigns have attempted to increase awareness of the important features to look out for. These include Be Clear on Cancer, a national public awareness campaign that aimed to improve early diagnosis of several cancer types by raising awareness of symptoms and encouraging people to see their doctor earlier. The campaign included specific messages about bowel cancer, such as "If you've had blood in your poo or looser poo for the last three

weeks, tell your doctor". "Never Too Young", from Bowel Cancer UK, aimed to raise awareness of bowel cancer in younger people. Cancer Research UK carries out numerous public information campaigns, as does the UK National Bowel Screening Programme. Research evidence on the effectiveness of these programmes is limited. An evaluation of Be Clear on Cancer found increases in colorectal cancer were mostly in the 'worried well', and increased the demand on NHS resources without any discernable improvements in cancer outcomes (55).

Conclusion

Improving the symptomatic colorectal cancer detection pathway is crucial for improving early diagnosis and patient outcomes. A range of strategies are required to achieve this improvement; this must be underpinned by high quality health research. Innovative approaches that prioritize the identification of patients who are at higher risk of developing the disease are needed, as well the development and implementation of more efficient and accessible diagnostic tools. By implementing innovative approaches, optimizing diagnostic tools, and improving patient education and awareness, we can improve the overall quality of care for patients with colorectal cancer.

Acknowledgements

With thanks to the Higgins family. SB is supported by an NIHR Advanced Fellowship (NIHR301666).

1. Incisive Health. Saving lives, averting costs [Internet]. 2014. Available from: www.incisivehealth.com.
2. Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *Br J Cancer* [Internet]. 2015;112 Suppl:S92-107. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25734382>
3. Mcphail S, Elliss-Brookes L, Shelton J, Ives A, Greenslade M, Vernon S, et al. Emergency presentation of cancer and short-term mortality. *Br J Cancer*. 2013;109(8).
4. Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. *Lancet Oncol*. 2020;
5. Geraghty J, Shaihi M, Devonport E, Sarkar S, Pearson MG, Bodger K. Reduced risk of emergency admission for colorectal cancer associated with the introduction of bowel cancer screening across England: a retrospective national cohort study. *Colorectal Disease*. 2018;20(2).
6. Elliss-Brookes L, McPhail S, Ives A, Greenslade M, Shelton J, Hiom S, et al. Routes to diagnosis for cancer - Determining the patient journey using multiple routine data sets. *Br J Cancer*. 2012;107(8):1220–6.
7. Biswas M, Ades AE, Hamilton W. Symptom lead times in lung and colorectal cancers: What are the benefits of symptom-based approaches to early diagnosis? *Br J Cancer*. 2015;112(2).
8. Møller H, Gildea C, Meechan D, Rubin G, Round T, Vedsted P. Use of the English urgent referral pathway for suspected cancer and mortality in patients with cancer: cohort study. *BMJ* [Internet]. 2015;h5102. Available from: <http://www.bmj.com/lookup/doi/10.1136/bmj.h5102>
9. Shaihi M, Thompson E, Kapoor N, Powell G, Sturgess RP, Stern N, et al. Variation in gastroscopy rate in English general practice and outcome for oesophagogastric cancer: Retrospective analysis of Hospital Episode Statistics. *Gut*. 2014;63(2).
10. Bailey SER, Abel GA, Atkins A, Byford R, Davies SJ, Mays J, et al. Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England. *Br J Cancer* [Internet]. 2021;(December 2020). Available from: <http://dx.doi.org/10.1038/s41416-020-01221-9>
11. NICE: National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. *Ng12* [Internet]. 2017;(June 2015). Available from: <https://www.nice.org.uk/guidance/ng12>
12. Nicholson BD, Hamilton W, Koshiaris C, Oke JL, Hobbs FDR, Aveyard P. The association between unexpected weight loss and cancer diagnosis in primary care: a matched cohort analysis of 65,000 presentations. *Br J Cancer*. 2020;122(12).
13. Price SJ, Gibson N, Hamilton WT, Bostock J, Shephard EA. Diagnoses after newly-recorded abdominal pain in primary care: Observational cohort study. *British Journal of General Practice*. 2022;72(721).

14. Bailey SER, Ukoumunne OC, Shephard EA, Hamilton W. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using UK electronic medical records and cancer registry data. *British Journal of General Practice*. 2017;67(659):e405–13.
15. Hopkins R, Bailey SER, Hamilton WT, Shephard EA. Microcytosis as a risk marker of cancer in primary care: A cohort study using electronic patient records. *British Journal of General Practice*. 2020;70(696):E457–62.
16. Frazzoni L, Laterza L, La Marca M, Zagari RM, Radaelli F, Hassan C, et al. Clinical value of alarm features for colorectal cancerA Meta-Analysis. *Endoscopy*. 2022;
17. Koo MM, Swann R, McPhail S, Abel GA, Ellis-Brookes L, Rubin GP, et al. Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study. *Lancet Oncol*. 2020;21(1).
18. Hamilton W, Round A, Sharp D, Peters T. Clinical features of colorectal cancer before diagnosis: a population-based case-control study. *Br J Cancer*. 2005;93:399–405.
19. Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng KK, Marshall T. The importance of anaemia in diagnosing colorectal cancer: a case–control study using electronic primary care records. *Br J Cancer* [Internet]. 2008;98(2):323–7. Available from: <http://www.scopus.com/inward/record.url?eid=2-s2.0-38549134054&partnerID=tZOtx3y1>
<http://www.nature.com/doi/10.1038/sj.bjc.6604165>
20. Nørrelund N, Nørrelund H. Colorectal cancer and polyps in patients aged 40 years and over who consult a GP with rectal bleeding. *Fam Pract*. 1996;13(2).
21. Nicholson BD, Hamilton W, O’Sullivan J, Aveyard P, Hobbs FDR. Weight loss as a predictor of cancer in primary care: A systematic review and meta-analysis. Vol. 68, *British Journal of General Practice*. 2018.
22. Hamilton W, Lancashire R, Sharp D, Peters TJ, Cheng KK, Marshall T. The risk of colorectal cancer with symptoms at different ages and between the sexes: A case-control study. *BMC Med*. 2009;7.
23. Panzuto F, Chiriatti A, Bevilacqua S, Giovannetti P, Russo G, Impinna S, et al. Symptom-based approach to colorectal cancer: Survey of primary care physicians in Italy. *Digestive and Liver Disease*. 2003;35(12).
24. Watson J, Hamilton F, Bailey SER, Mounce L, Hamilton W. Clinical implications of increased testing in primary care. *Br Med J*. 2019;364 :l175.
25. Stapley S, Peters T, Sharp D, Hamilton W. The mortality of colorectal cancer in relation to the initial symptom and to the duration of symptoms: a cohort study in primary care. *Br J Cancer*. 2006;95(10):1321–5.
26. Cleary J, Peters TJ, Sharp D, Hamilton W. Clinical features of colorectal cancer before emergency presentation: A population-based case - Control study. *Fam Pract*. 2007;24(1):3–6.
27. Kinar Y, Kalkstein N, Akiva P, Levin B, Half EE, Goldshtein I, et al. Development and validation of a predictive model for detection of colorectal cancer in primary care by analysis of

- complete blood counts: A binational retrospective study. *Journal of the American Medical Informatics Association*. 2016;23(5).
28. Neal RD, Din NU, Hamilton W, GBRoumunne OC, Carter B, Stapley S, et al. Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: Analysis of data from the GBR General Practice Research Database. *Br J Cancer* [Internet]. 2014;110(3):584–92. Available from: <http://dx.doi.org/10.1038/bjc.2013.791>
 29. Ellis BG, Thompson MR. Factors identifying higher risk rectal bleeding in general practice. *British Journal of General Practice*. 2005;55(521).
 30. Wiering B, Lyratzopoulos G, Hamilton W, Campbell J, Abel G. Concordance with urgent referral guidelines in patients presenting with any of six “alarm” features of possible cancer: a retrospective cohort study using linked primary care records. *BMJ Qual Saf*. 2022;31(8).
 31. Giannakeas V, Narod SA. Incidence of Cancer among Adults with Thrombocytosis in Ontario, Canada. *JAMA Netw Open*. 2021;4(8).
 32. Price S, Spencer A, Medina-Lara A, Hamilton W. Availability and use of cancer decision-support tools: a cross-sectional survey of UK primary care. *British Journal of General Practice*. 2019;
 33. Calitri R, Mounce L, Abel G, Campbell J, Spencer A, Medina-Lara A, et al. Protocol for a pragmatic cluster randomised controlled trial assessing the clinical effectiveness and cost effectiveness of electronic risk-assessment tools for cancer for patients in general practice (ERICA). *Trials*. 2019;20(Supplement 1).
 34. NICE external assessment group. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care | Guidance and guidelines | NICE. Dg30. 2017;(July 2017).
 35. Price S, Spencer A, Zhang X, Ball S, Lyratzopoulos G, Mujica-Mota R, et al. Trends in time to cancer diagnosis around the period of changing national guidance on referral of symptomatic patients: A serial cross-sectional study using UK electronic healthcare records from 2006–17. *Cancer Epidemiol*. 2020;69.
 36. Done JZ, Fang SH. Young-Onset Colorectal Cancer: A Review. *World J Gastrointest Oncol*. 2021;13(8).
 37. Venugopal A, Stoffel E. Colorectal Cancer in Young Adults. *Curr Treat Options Gastroenterol*. 2019;17(1):89–98.
 38. Stapley SA, Rubin GP, Alsina D, Shephard EA, Rutter MD, Hamilton WT. Clinical features of bowel disease in patients aged <50 years in primary care: A large case-control study. *British Journal of General Practice*. 2017;67(658).
 39. Turvill J, Aghahoseini A, Sivarajasingham N, Abbas K, Choudhry M, Polyzois K, et al. Faecal calprotectin in patients with suspected colorectal cancer: A diagnostic accuracy study. *British Journal of General Practice*. 2016;66(648).
 40. Kim TJ, Kim ER, Hong SN, Chang DK, Kim YH. Long-term outcome and prognostic factors of sporadic colorectal cancer in young patients: A large institutional-based retrospective study. *Medicine (United States)*. 2016;95(19).

41. Balmaña J, Balaguer F, Cervantes A, Arnold D. Familial risk-colorectal cancer: ESMO clinical practice guidelines. *Annals of Oncology*. 2013;24(SUPPL.6).
42. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer). *New England Journal of Medicine*. 2005;352(18).
43. Newton K, Green K, Laloo F, Evans DG, Hill J. Colonoscopy screening compliance and outcomes in patients with lynch syndrome. *Colorectal Disease*. 2015;17(1).
44. Toh JWT, Hui N, Collins G, Phan K. Survival outcomes associated with Lynch syndrome colorectal cancer and metachronous rate after subtotal/total versus segmental colectomy: Meta-analysis. Vol. 172, *Surgery (United States)*. 2022.
45. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). *Lancet Oncol*. 2008;9(8).
46. Bailey SE, Butler CA, Katsampouris E, Kessler L, Quaife SL, Saya S, et al. Determining the role of genetic risk scores in symptomatic cancer detection. Vol. 73, *The British journal of general practice : the journal of the Royal College of General Practitioners*. 2023.
47. Green HD, Merriel SWD, Oram RA, Ruth KS, Tyrrell J, Jones SE, et al. Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank. *Br J Cancer*. 2022 Aug 18;
48. Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: A systematic review and meta-analysis of cohort studies. *Eur J Epidemiol*. 2011;26(11).
49. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JPA. Type 2 diabetes and cancer: Umbrella review of meta-analyses of observational studies. *BMJ (Online)*. 2015.
50. Xuan K, Zhao T, Sun C, Patel AS, Liu H, Chen X, et al. The association between hypertension and colorectal cancer: A meta-analysis of observational studies. *European Journal of Cancer Prevention*. 2020;
51. Whitlock K, Gill RS, Birch DW, Karmali S. The association between obesity and colorectal cancer. *Gastroenterology Research and Practice*. 2012.
52. Taylor CC, Millien VO, Hou JK, Massarweh NN. Association Between Inflammatory Bowel Disease and Colorectal Cancer Stage of Disease and Survival. *Journal of Surgical Research*. 2020;247.
53. Raut JR, Guan Z, Schrotz-King P, Brenner H. Fecal DNA methylation markers for detecting stages of colorectal cancer and its precursors: A systematic review. Vol. 12, *Clinical Epigenetics*. 2020.
54. Deding U, Valdivia PC, Koulaouzidis A, Baatrup G, Toth E, Spada C, et al. Patient-reported outcomes and preferences for colon capsule endoscopy and colonoscopy: A systematic review with meta-analysis. Vol. 11, *Diagnostics*. 2021.
55. Peacock O, Clayton S, Atkinson F, Tierney GM, Lund JN. "Be Clear on Cancer": The impact of the UK National Bowel Cancer Awareness Campaign. *Colorectal Disease*. 2013;15(8).

